DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20170830

A Comparative study to assess the effectiveness and safety of cilnidipine versus amlodipine in patients with newly diagnosed essential hypertension: insights from a single centre prospective observational study

Ramya Y. S., Jayanthi C. R., Raveendra K. R., Pradeep Kumar B. T.

Abstract


Background: Calcium channel blockers (CCBs) are proposed to play a pivotal role for the management and control of hypertension. Dihydropyridine-type calcium channel blockers (CCBs) like Amlodipine are frequently used because for their strong antihypertensive and minimal adverse side effects. However, it is commonly associated with the causation of pedal edema among the patients. Cilnidipine, which is a novel new generation calcium channel blocker, is presumed to cause lesser pedal edema with a satisfactory clinical control of hypertension along with negligible side effects. This study was carried out to compare clinical effectiveness and safety profile between Amlodipine and Cilnidipine.

Methods: A prospective, randomized, open label study of 12 weeks’ duration was conducted amongst 60 patients with newly diagnosed essential hypertension. 30 patients of one group received Tab. Amlodipine 5 mg and 30 patients of same age groups received Tab. Cilnidipine 10mg.

Results: There was a highly statistically significant decrease in the level of blood pressure in the Cilnidipine group compared to the Amlodipine group mainly at day 90 (P<0.001). Cilnidipine treated group had a fall in blood pressure of 23 ± 8 mmHg and the Amlodipine group had a decrease in the blood pressure of 12±7mmHg. Additionally, there was also significant reduction in pulse rate in the cilnidipine group. Only 4 patients in the Cilnidipine group developed ankle edema which completely disappeared at the end of 12 weeks of therapy compared to 9 patients in the Amlodipine group which persistently worsened at the completion of the study.

Conclusions: Our study concluded that cilnidipine was a well-tolerated anti-hypertensive drug amongst patients with newly diagnosed essential hypertension and associated with minor adverse effects.


Keywords


Amlodipine, Ankle edema, Cilnidipine, Newly diagnosed essential hypertension

Full Text:

PDF

References


Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-72.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-26.

Kloke HJ, Branten AJ, Huysmans FT. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calciumchannel blockers? Kidney Int. 1998;53:1559-73.

The safety of amlodipine. Osterloh I Am Heart J. 1989 Nov;118(5 Pt 2):1114-9.

Xu G, Wu H, Du B, Qin L. The efficacy and safety of cilnidipine on mild to moderate essential hypertension: A systematic review and meta-analysis of randomized controlled trials in Chinese patients. Cardiovasc Hematol Disord Drug Targets. 2012;12:56-62.

Chandra KS, Ramesh G. The fourth-generation Calcium channel blocker: Cilnidipine. Indian Heart Journal. 2013;65(6):691-5.

Gillman MW, Kannel WB, Belanger A, Agostino RB. Influence of heart rate on mortality among person with hypertension: the Framingham Study. Am Heart J. 1993;125:1148-54.

Sataka K, Shirotani M, Yoshida H. Effects of Amlodipine and Cilnidipine on cardiac sympathetic nervous system and neuro hormonal status in essential hypertension. Hypertension. 1999;33:1447-52.

Morimoto S, Takeda K, Oguni A. Reduction of white coat effect by Cilnidipine in essential hypertension. Am J Hypertens. 2001;14:1053-7.

Zhou X, Ono H, Ono Y, Frohlich ED. N-and L-type calcium channel antagonist improves glomerular dynamics, reverse severe nephrosclerosis and inhibits apoptosis and proliferation in an LNAME/SHR model. J Hypertens. 2002;20:993-1000.

Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Takahashashi K. Antiproteinuric effect of the calcium channel blocker Cilnidipine added to rennin angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72:1543-9.